RankingsLogo

Biogen Inc.

Biogen Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Biogen Inc. is a biotechnology company that specializes in treating neurological diseases. Through research, development, and distribution, this company helps people access treatments for disorders including Alzheimer’s, Multiple Sclerosis, and Spinal Muscular Atrophy.

Ticker: BIIB

Humankind Value: $84.5 B

Revenue: $13.4 B

Market Cap: $32.1 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Biogen Inc. has earned a spot in our top 100. The greatest contributors to this positive outcome are Healthcare R&D ($41.0 B), Pharmaceuticals ($39.3 B), and Economic Value ($3.8 B). The value associated with Healthcare R&D and Pharmaceuticals includes the annual impact of an estimated 1,500,000 additional years lived by people worldwide. This firm can increase its Humankind Value by addressing Greenhouse Gases (-$870.5 M) and Air Pollution (-$110.3 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attributed to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings